Literature DB >> 25943187

A Comprehensive Review of Drug-Drug Interactions with Metformin.

Tore Bjerregaard Stage1, Kim Brøsen, Mette Marie Hougaard Christensen.   

Abstract

Metformin is the world's most commonly used oral glucose-lowering drug for type 2 diabetes, and this is mainly because it protects against diabetes-related mortality and all-cause mortality. Although it is an old drug, its mechanism of action has not yet been clarified and its pharmacokinetic pathway is still not fully understood. There is considerable inter-individual variability in the response to metformin, and this has led to many drug-drug interaction (DDI) studies of metformin. In this review, we describe both in vitro and human interaction studies of metformin both as a victim and as a perpetrator. We also clarify the importance of including pharmacodynamic end points in DDI studies of metformin and taking pharmacogenetic variation into account when performing these studies to avoid hidden pitfalls in the interpretation of DDIs with metformin. This evaluation of the literature has revealed holes in our knowledge and given clues as to where future DDI studies should be focused and performed.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25943187     DOI: 10.1007/s40262-015-0270-6

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  99 in total

1.  Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain.

Authors:  M R Owen; E Doran; A P Halestrap
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  A twin study of the trough plasma steady-state concentration of metformin.

Authors:  Tore B Stage; Per Damkier; Rasmus S Pedersen; Mette M H Christensen; Lene Christiansen; Kaare Christensen; Kim Brosen
Journal:  Pharmacogenet Genomics       Date:  2015-05       Impact factor: 2.089

3.  Five things to know about...metformin and intravenous contrast.

Authors:  Mark Otto Baerlocher; Murray Asch; Andy Myers
Journal:  CMAJ       Date:  2012-10-09       Impact factor: 8.262

4.  Effect of voglibose on the pharmacokinetics of metformin in healthy Korean subjects.

Authors:  Ho-Sook Kim; Minkyung Oh; Eun Ji Kim; Geun Seog Song; Jong-Lyul Ghim; Ji-Hong Shon; Dong-Hyun Kim; Jae-Gook Shin
Journal:  Int J Clin Pharmacol Ther       Date:  2014-11       Impact factor: 1.366

5.  Intake of St John's wort improves the glucose tolerance in healthy subjects who ingest metformin compared with metformin alone.

Authors:  Tore Bjerregaard Stage; Rasmus Steen Pedersen; Per Damkier; Mette Marie Hougaard Christensen; Søren Feddersen; John Teilmann Larsen; Kurt Højlund; Kim Brøsen
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

6.  Mechanism by which metformin reduces glucose production in type 2 diabetes.

Authors:  R S Hundal; M Krssak; S Dufour; D Laurent; V Lebon; V Chandramouli; S E Inzucchi; W C Schumann; K F Petersen; B R Landau; G I Shulman
Journal:  Diabetes       Date:  2000-12       Impact factor: 9.461

7.  Oxybutynin and trospium are substrates of the human organic cation transporters.

Authors:  Birger Wenge; Joachim Geyer; Heinz Bönisch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-07       Impact factor: 3.000

8.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study.

Authors:  Tanja Dujic; Kaixin Zhou; Louise A Donnelly; Roger Tavendale; Colin N A Palmer; Ewan R Pearson
Journal:  Diabetes       Date:  2014-12-15       Impact factor: 9.461

Review 9.  Pharmacogenetic variation and metformin response.

Authors:  Suning Chen; Jie Zhou; Miaomiao Xi; Yanyan Jia; Yan Wong; Jinyi Zhao; Likun Ding; Jian Zhang; Aidong Wen
Journal:  Curr Drug Metab       Date:  2013-12       Impact factor: 3.731

10.  Proton pump inhibitors do not impair the effectiveness of metformin in patients with diabetes.

Authors:  James Flory; Kevin Haynes; Charles E Leonard; Sean Hennessy
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

View more
  28 in total

1.  Endogenous glucose production increases in response to metformin treatment in the glycogen-depleted state in humans: a randomised trial.

Authors:  Mette Marie H Christensen; Kurt Højlund; Ole Hother-Nielsen; Tore B Stage; Per Damkier; Henning Beck-Nielsen; Kim Brøsen
Journal:  Diabetologia       Date:  2015-08-14       Impact factor: 10.122

2.  Drug-drug interaction of cefiderocol, a siderophore cephalosporin, via human drug transporters.

Authors:  Takayuki Katsube; Shiro Miyazaki; Yukitoshi Narukawa; Martha Hernandez-Illas; Toshihiro Wajima
Journal:  Eur J Clin Pharmacol       Date:  2018-04-07       Impact factor: 2.953

3.  Assessment of Substrate-Dependent Ligand Interactions at the Organic Cation Transporter OCT2 Using Six Model Substrates.

Authors:  Philip J Sandoval; Kimberley M Zorn; Alex M Clark; Sean Ekins; Stephen H Wright
Journal:  Mol Pharmacol       Date:  2018-06-08       Impact factor: 4.436

4.  Hepatic exposure of metformin in patients with non-alcoholic fatty liver disease.

Authors:  Elias Immanuel Ordell Sundelin; Lars Christian Gormsen; Sara Heebøll; Mikkel Holm Vendelbo; Steen Jakobsen; Ole Lajord Munk; Søren Feddersen; Kim Brøsen; Stephen Jacques Hamilton-Dutoit; Steen Bønløkke Pedersen; Henning Grønbaek; Niels Jessen
Journal:  Br J Clin Pharmacol       Date:  2019-06-18       Impact factor: 4.335

5.  Limited sampling strategy for determining metformin area under the plasma concentration-time curve.

Authors:  Ana Beatriz Santoro; Tore Bjerregaard Stage; Claudio José Struchiner; Mette Marie Hougaard Christensen; Kim Brosen; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2016-07-24       Impact factor: 4.335

Review 6.  Renal Drug Transporters and Drug Interactions.

Authors:  Anton Ivanyuk; Françoise Livio; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacokinet       Date:  2017-08       Impact factor: 6.447

7.  Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Authors:  Elise J Smolders; Angela Colbers; Clara T M M de Kanter; Kirsten Velthoven-Graafland; Leonie T Wolberink; Noor van Ewijk-Beneken Kolmer; Joost P H Drenth; Rob E Aarnoutse; Cees J Tack; David M Burger
Journal:  Br J Clin Pharmacol       Date:  2017-06-06       Impact factor: 4.335

8.  Influence of pharmacogenetic polymorphisms and demographic variables on metformin pharmacokinetics in an admixed Brazilian cohort.

Authors:  Ana Beatriz Santoro; Mariana Rodrigues Botton; Claudio José Struchiner; Guilherme Suarez-Kurtz
Journal:  Br J Clin Pharmacol       Date:  2018-02-26       Impact factor: 4.335

9.  Route-specific association of progestin therapy and concurrent metformin use in obese women with complex atypical hyperplasia.

Authors:  Koji Matsuo; Rachel S Mandelbaum; Marcia Ciccone; Mahdi Khoshchehreh; Heena Pursuwani; Elise B Morocco; Shinya Matsuzaki; Christina E Dancz; Begum Ozel; Richard J Paulson; Lynda Roman
Journal:  Int J Gynecol Cancer       Date:  2020-05-05       Impact factor: 3.437

Review 10.  Metformin as a geroprotector: experimental and clinical evidence.

Authors:  Veronika Piskovatska; Nadiya Stefanyshyn; Kenneth B Storey; Alexander M Vaiserman; Oleh Lushchak
Journal:  Biogerontology       Date:  2018-09-25       Impact factor: 4.277

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.